Penn Researchers Prove "Short-Cut" Function Of Myelin Sheath Channel: BetterUnderstanding Of Myelin Should Lead To Therapies For Neuropathies

August 24, 1998

Diseases of the covering of nerve cells -- called the myelin sheath -- can be quite debilitating and affect hundreds of thousands of people each year. Multiple sclerosis, which afflicts nerve cells in the brain, is one of the most well known. As part of a long-term investigation, researchers at the University of Pennsylvania Medical Center have demonstrated for the first time how a biochemical channel important for the exchange of cell nutrients links the multiple layers of myelin to the outside space.

"This is a big breakthrough for understanding how myelin works, with implications for all demyelinating diseases, including multiple sclerosis," says Steven Scherer, MD, PhD, associate professor of neurology, who collaborated with Rita Balice-Gordon, PhD, assistant professor of neuroscience, and former Penn combined degree student Linda J. Bone, MD, PhD, on this study.

In earlier work, mutations in components of the channel were associated with inherited forms of neuropathies. Specifically, five years ago, former Penn neurologist Kenneth H. Fischbeck, MD, and Scherer reported that mutations in connexin32 -- a protein found in myelin-producing as well as other cells -- cause X-linked Charcot-Marie-Tooth disease (CMTX), a genetic disorder that produces progressive degeneration of peripheral nerves. One out of 3,000 people suffer from Charcot-Marie-Tooth disease, with 10 to 20 percent of those having this particular inherited form. This led the research team to reappraise the function of connexin32 in myelinating cells. They hypothesized that connexin32 forms part of a six-sided channel wall -- called the gap junction -- that couples the multiple layers of the sheath to the outside, extracellular space. "Our most recent work directly demonstrates the channel's function in the myelin sheath for the first time," says Scherer. The researchers report their findings in the August 24 issue of the Journal of Cell Biology.

The myelin sheath is a unique cellular adaptation found in most vertebrates. "It's very peculiar in that it's like a sleeping bag all rolled up around the axon, the nerve cell inside," remarks Scherer. The sheath allows for the fast conduction times seen in higher vertebrates. Because of its many layers, the sheath might limit diffusion of necessary substances to and from the cell. "But nature has circumvented that problem with gap junctions," he explains.

"These channels provide a radial path for ions and small molecules that we believe is a thousand times shorter and a million times faster than traveling the entire circumference of the sheath," says Balice-Gordon. "We used intracellular dye injections in cultures of myelinating cells and video microscopy to directly demonstrate that this short-cut exists."

In labs all over the world, about 160 mutations have been discovered for connexin32. One group of mutated proteins can still form functional gap junctions, but it remains to be seen how these result in inherited neuropathies. In general, though, as the myelinating cells break down due to these mutations, they impart pathological changes onto the axon. "The mechanism of that might be related to potassium ion movement through the gap junctions, but this is just a hypothesis right now," states Scherer.

"Certainly in the narrowest sense this research ought to lead to some treatments for CMTX," adds Scherer. "We ought to be able to someday design therapies based on our growing knowledge of how the mutations affect the sheath and the passage of ions through gap junctions." So far, the team has been able to express in transgenic mice both normal and mutant connexin32 genes in myelinating cells. This work indicates that these mutations have altered the function of the cells and could account for the demyelinating neuropathies seen in the transgenic mice.

This research was supported by grants from the National Institutes of Health and the Muscular Dystrophy Association.

Editor's Note: Dr. Scherer can be reached at (215) 573-3198 or scherer@mail.med.upenn.edu.

The University of Pennsylvania Medical Center's sponsored research ranks third in the United States, based on grant support from the National Institutes of Health, the primary funder of biomedical research in the nation. In federal fiscal year 1997, the medical center received $175 million. News releases from the medical center are available to reporters by direct E-mail, fax, or U.S. mail, upon request. They are also posted to the center's website (http://www.med.upenn.edu); EurekAlert! (http://www.eurekalert.org), a resource sponsored by the American Association for the Advancement of Science; and Newswise (http://www.newswise.com).
-end-


University of Pennsylvania School of Medicine

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.